Publications

5891 Results

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

Authors
M Redman;B Goldman;M LeBlanc;A Schott;LH Baker
Journal / Conference
Clinical Cancer Research, 19(10):2646-2656;
Year
2013
Research Committee(s)
Brain, Breast, Gastrointestinal, Gynecologic, Lung, Lymphoma, and Myeloma
PMID
PMID23669424
PMC
PMC4131693
Study Number(s)
S0001, S0124, SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12), SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195), SWOG-9308, SWOG-9313, SWOG-9321, SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415), SWOG-9438, SWOG-9509

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

Authors
BP Schneider;RJ Gray;M Radovich;F Shen;G Vance;L Li;G Jiang;J Gralow;MN Dickler;M Cobleigh;EA Perez;T Shenkier;K Vang Nielsen;S Muller;A Thor;G Sledge, Jr;JA Sparano;NE Davidson;SS Badve
Journal / Conference
Clinical Cancer Research 19(5):1281-1289
Year
2013
Research Committee(s)
Breast
PMID
PMID23340303
PMC
PMC3594423
Study Number(s)
CTSU/E2100

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Authors
CF de Larrea;RA Kyle;BGM Durie;H Ludwig;S Usmani;DH Vesole;R Hajeck;JF San Miguel;O Sezer;P Sonneveld;SK Kumar;A Mahindra;RL Comenzo;A Palumbo;A Mazumber;KC Anderson;PG Richardson;AZ Badros;J Caers;M Cavo;X LeLeu;MA Dimopoulos;CS Chim;R Schots;A Noeul;D Fantl;UH Mellqvist;O Landgren;A Chanan-Khan;P Moreau;R Fonseca;G Merlini;JJ Lahuerta;J Blade;RZ Orlowski;JJ Shah
Journal / Conference
Leukemia 27(4):780-91
Year
2013
Research Committee(s)
Myeloma
PMID
PMID23288300
PMC
n/a - review article

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective Phase 2 trials

Authors
G Sonpavde;G Pond;R Fougeray;TK Choueiri;A Qu;DJ Vaughn;G Niegisch;P Albers;ND James;YN Wong;YJ Ko;SS Sridhar;MD Galsky;DP Petrylak;U Vaishampayan;A Khan;N Vogelzang;T Beer;WM Stadler;PH O'Donnell;CN Sternberg;JE Rosenberg
Journal / Conference
European Urology, 63(4):717-723
Year
2013
Research Committee(s)
Genitourinary
PMID
PMID23206856
PMC
PMC4127896
Study Number(s)
S0031, S0306

Cooperative group clinical trials in general thoracic surgery: report from the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical Club

Authors
M Allen;D Wigle;K Kernstine
Journal / Conference
Annals of Thoracic Surgery 95(2):750-756
Year
2013
Research Committee(s)
Lung
PMID
PMID23336898
PMC
Reviews not within the scope of the Public Access Policy

Factors associated with retention of African-American and white participants in a prostate cancer prevention trial

Authors
JA Hermos;K Arnold;E Cook;K Anderson;J Probstfield
Journal / Conference
Society for Clinical Trials Annual Meeting (May 19-22, 2013, Boston, MA), poster presentation
Year
2013
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Clinical, genomic, and imaging predictors of malignancy: analysis ofthe first U.S. cooperative group prospective clinical trial in symptomatic monoclonal gammopathies (SWOG S0120)

Authors
MV Dhodapkar;R Sexton;S Waheed;SZ Usmani;XD Papanikolaou;BP Nair;NM Petty;JD Shaughnessy;A Hoering;J Crowley;RZ Orlowski;B Barlogie
Journal / Conference
Journal of Clinical Oncology 31(suppl; abstr 8515); ASCO annual meeting 2013, oral presentation
Year
2013
Research Committee(s)
Myeloma
Study Number(s)
S0120

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

Authors
S Nand;M Othus;JE Godwin;CL Willman;TH Norwood;DS Howard;SE Coutre;HP Erba;FR Appelbaum
Journal / Conference
Blood 122(20):3432-3439;
Year
2013
Research Committee(s)
Leukemia
PMID
PMID24092933
PMC
PMC3829116
Study Number(s)
S0703

Should modest elevations in prostate specific antigen or international prostate symptom score, or their rates of increase over time, be used as surrogate measures of incident benign prostatic hyperplasia?

Authors
J Schenk;R Hunter-Merrill;Y Zheng;R Etzioni;R Gulati;C Tangen;IM Thompson;A Kristal
Journal / Conference
American Journal of Epidemiology 178(5):741-751;
Year
2013
Research Committee(s)
Cancer Control
PMID
PMID23813705
PMC
PMC3755644
Study Number(s)
SWOG-9217

Phase IIB randomized double-blind placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer: SWOG S0812

Authors
K Crew;D Lew;D Hershman;S Refice;G Anderson;G Hortobagyi;G Goodman;P Brown
Journal / Conference
San Antonio Breast Cancer Symposium, abstr. OT3-3-02; poster presentation;
Year
2013
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0812